...
首页> 外文期刊>Experimental and therapeutic medicine >Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy
【24h】

Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy

机译:瑞克库什科患者患有先进的非小细胞肺癌接受第一线化疗的全基因组基因表达变化及血液学作用

获取原文
获取原文并翻译 | 示例

摘要

It has been demonstrated that the traditional Chinese medicine rikkunshito, ameliorates anorexia in several types of human cancer and attenuates lung injury by inhibiting neutrophil infiltration. The current study investigated the clinical and hematological effects of rikkunshito and its underlying mechanisms of action in the treatment of advanced non-small cell lung cancer (NSCLC). The Illumina microarray BeadChip was used to analyze the whole-genome expression profiles of peripheral blood mononuclear cells in 17 patients with advanced NSCLC. These patients were randomized to receive combination chemotherapy (cisplatin and gemcitabine) with (n=9, CTH+R group) or without (n=8, CTH group) rikkunshito. The primary endpoint was the treatment response and the categories of the scales of anorexia, nausea, vomiting and fatigue; secondary endpoints included the hematological effect and whole genome gene expression changes. The results of the current study indicated that there were no significant differences in clinical outcomes, including treatment response and toxicity events, between the two groups. Median one-year overall survival (OS) was 12 months in the CTH group and 11 months in the CTH+R group (P=0.058 by log-rank test), while old age (>60 years old) was the only independent factor associated with one-year OS (hazard ratio 1.095, 95% confidence interval, 1.09-1.189, P=0.030). Patients in the CTH+R group experienced significantly greater maximum decreases in both white cell count (P=0.034) and absolute neutrophil count (P=0.030) from the baseline. A total of 111 genes associated with neutrophil apoptosis, the cell-killing ability of neutrophils, natural killer cell activation and B cell proliferation were up-regulated following rikkunshito treatment. A total of 48 genes associated with neutrophil migration, coagulation, thrombosis and type I interferon signaling were down-regulated following rikkunshito treatment. Rikkunshito may therefore affect the blood neutrophil count when used with combination chemotherapy in patients with NSCLC, potentially by down-regulating prostaglandin-endoperoxidase synthase 1, MPL, AMICAI and junctional adhesion molecule 3, while up-regulating elastase, neutrophil expressed, proteinase 3, cathepsin G and cluster of differentiation 24.
机译:已经证明,中医牛克汗,通过抑制中性粒细胞渗透来改善几种人类癌症的厌食并衰减肺损伤。目前的研究调查了Rikkunshito的临床和血液学效应及其在治疗晚期非小细胞肺癌(NSCLC)中的潜在作用机制。 Illumina微阵列珠芯片用于分析17例高级NSCLC患者外周血单核细胞的全基因组表达谱。这些患者随机接受(N = 9,CTH + R基团)或没有(n = 8,CTH组)Rikkunshito的组合化疗(顺铂和吉西他滨)。主要终点是治疗反应和厌食,恶心,呕吐和疲劳的尺度的类别;次要终点包括血液学效应和全基因组基因表达的变化。目前研究的结果表明,两组之间的临床结果没有显着差异,包括治疗反应和毒性事件。中位数一年的整体生存(OS)在CTH组和Cth + R组中的11个月内为12个月(Log-Rank测试的P = 0.058),而老年(> 60岁)是唯一的独立因素与一年的OS相关联(危险比1.095,95%置信区间,1.09-1.189,P = 0.030)。 Cth + R组中的患者在基线中具有明显更大的白细胞计数(P = 0.034)和绝对中性粒细胞计数(P = 0.030)。在Rikkunshito治疗后,共有111个与中性粒细胞凋亡,中性粒细胞,自然杀伤细胞活化和B细胞增殖的细胞杀伤能力。在Rikkunshito治疗后,共有48个与中性粒细胞迁移,凝血,血栓形成和I型干扰素信号传导的基因。因此,当与NSCLC患者的组合化疗一起使用时,RIKKUNSHITO可能会影响血液中性粒细胞计数,可能通过抑制前列腺素 - 内透氧化酶合成酶1,MPL,AMICAI和连接粘附分子3,同时升压弹性蛋白酶,中性粒细胞表达,蛋白酶3,组织蛋白酶G和分化簇24。

著录项

  • 来源
  • 作者单位

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Dept Chinese Med Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Ctr Translat Res Biomed Sci Kaohsiung 83301 Taiwan;

    Chiayi Chang Gung Mem Hosp Dept Chinese Med Chiayi 61361 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Rheumatol Kaohsiung 83301 Taiwan;

    Chang Gung Univ Grad Inst Clin Med Sci Coll Med Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Rheumatol Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

    Kaohsiung Chang Gung Mem Hosp Div Pulm &

    Crit Care Med 123 Ta Pei Rd Kaohsiung 83301 Taiwan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学 ;
  • 关键词

    rikkunshito; non-small cell lung cancer; chemotherapy; microarray gene expression; neutropenia;

    机译:rikkunshito;非小细胞肺癌;化疗;微阵列基因表达;中性粒细胞病;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号